|
Strides Pharma Science in its consolidated financial results for Q1 FY26 ended June 30, 2025 has registered revenues to the tune of Rs. 1,119.7 crore reporting a growth of 6.2 per cent YoY compared to the corresponding quarter last year at Rs. 1,190.4 crore. In this quarter EBITDA grew 14.8% YoY to Rs. 218.1 crore with EBITDA margin at 19.5%, grew 150 bps YoY.
The Bengaluru-based company’s operational PAT was at Rs.114 crore with a growth of 80.6% YoY. Its reported PAT was at Rs. 105.6 crore. The operational PAT is equal to the reported PAT from continuing operations excluding exceptional items. Operational EPS was at Rs 12.4. The US revenue was at $71million with a growth of 7% YoY.
Badree Komandur, MD & Group CEO, Strides Pharma said, “We are pleased to report a solid start to the year, marked by consistent growth and enhanced profitability. Our focus on cost management and diligent execution has enabled us to deliver robust results. The EBITDA margin improved to 19.5%, an increase of 150bps YoY. Strong operating leverage contributed to the highest-ever quarterly PAT, resulting in an operational EPS of Rs. 12.4. Consequently, ROCE (return on capital employed) stands at 15.1% for Q1. The company will enhance its R&D efforts during the year to drive sustainable long-term growth.”
|